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Aim: We have shown that diabetes alters structural and functional
properties of the cerebrovasculature in part by the activation of the
endothelin (ET) system in a glucose-dependent manner. Here, we
tested the hypothesis that established diabetes-induced vascular
dysfunction and remodeling could be reversed by glycemic control or
dual ET-1 receptor antagonism. Methods: Studies were performed in
non-obese type-2 diabetic Goto–Kakizaki (GK) rats. GK rats were
treated with vehicle, metformin (300 mg/kg/day) or dual ET-receptor
antagonist bosentan (100 mg/kg/day) after onset of remodeling from
18 to 22 weeks by oral gavage. Additional groups included vehicle-
treated 10 or 18-week GK rats. Blood glucose and mean arterial blood
pressure (MAP) were monitored weekly. At termination, middle
cerebral artery (MCA) lumen diameter, media thickness (MT), media:
lumen (M:L) ratio, cross-sectional area (CSA) and myogenic-tone
were measured using pressurized arteriograph (n= 8–14/group).
Results: GK MAP was 102, 105 and 119 for vehicle, metformin and
bosentan, respectively. 18 and 22-week diabetic GK rats displayed
increased M:L ratio and CSA, but decreased lumen diameter and
myogenic tone compared to 10-week animals. Glycemic control with
metformin signiﬁcantly improved blood glucose and partially reversed
vascular remodeling by decreasing theMT,M:L ratio and CSA.Myogenic
tonewas improved only at lower pressures. Bosentan improved theMT
and M:L ratio and did not affect CSA. Bosentan showed a signiﬁcant
improvement in MCA myogenic-tone over the pressure range despite
elevated MAP. Conclusions: Glycemic control or ET-1 antagonism can
partially reverse diabetes-induced cerebrovascular remodeling and
dysfunction. These results strongly suggest that either approach offers
a therapeutic beneﬁt and combination treatments need to be tested.
doi:10.1016/j.lfs.2014.01.044
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Aims: Up-regulation of the endothelin (ET) system in type-2 diabetes
leads to increased contraction and decreased relaxation in basilar artery.
We showed that 1) ET receptor antagonism prevents diabetes-mediated
cerebrovascular dysfunction, and 2) glycemic control prevents activation
of the ET system in diabetes. The goal of the current study was to
determine whether and to what extent glycemic control or ET-receptor
antagonism reverses established cerebrovascular dysfunction in diabetes.
Methods: Non-obese type-2 diabetic Goto–Kakizaki (GK) rats were
administered either vehicle, metformin (300 mg/kg/day) or dual ET-
receptor antagonist bosentan (100 mg/kg) for 4 weeks starting at 18-
weeks after established cerebrovascular dysfunction (n= 6–8/group).
Blood glucose and blood pressure were monitored weekly. At termina-
tion, basilar arterieswere collected and cumulative dose–response curves
to ET-1 (1–500 nM), 5-HT (1–1000 nM) and acetylcholine (Ach, 1 nM–
5 μM) were studied by wire myograph. Results: Only metformin
decreased blood glucose. MAP was 102, 105 and 119 for vehicle,
metformin and bosentan, respectively. The magnitude of basilar artery
constriction in response to KCl was similar among groups. Interestingly,
constriction to ET-1 and 5-HT (area under curve, AUC) was greater in
treated animals as compared to vehicle-treated GK rats; however, there
was no difference in Rmax or EC50. Both bosentan and metformin
improved sensitivity to Ach and only bosentan increased relaxation
(Rmax and AUC) despite elevated blood pressure. Conclusion: These
results suggest that augmented contractile response to vasoactive agents
is not improved by glycemic control or ET-receptor antagonism but ET-
receptor antagonism is effective in improving relaxation response even if
started after established cerebrovascular dysfunction and offers thera-
peutic potential.
doi:10.1016/j.lfs.2014.01.045
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In patients with type I diabetes mellitus poor management causes a
drastic rise in glucose levels resulting in diabetic ketoacidosis (DKA).
About 1% of DKA episodes can be complicated by cerebral edema. ET
and its receptors are involved in the regulation of cerebral blood ﬂow.
We studied the effect of ETA receptor antagonists in a rat model of DKA.
DKAwas produced by streptozotocin (150 mg/kg, ip). Group 1: Control
(non-diabetic) animals administered citrate. Animals that developed
DKA were divided in ﬁve additional groups. Group II: DKA animals
without treatment; Group III: DKA animals given saline; Group IV: DKA
animals given saline and insulin of 1.5 u/kg/h; Group V: DKA animals
given saline, insulin of 1.5 u/kg/h and BMS-182874 (9 mg/kg); and
Group VI: DKA animals given saline, insulin of 1.5 u/kg/h and BQ123
(1 mg/kg). Blood glucose and ketones markedly increased by day 4 in
DKA rats. Saline/insulin treatment in DKA rats increased the plasma and
brain ET-1 levels which were not affected by BMS-182874 or BQ123
treatment. There was no change in the expression of ETB receptors in
the brain, however, ETA receptor expression increased in DKA rats and
was not altered following treatment with insulin, BMS-182874 or
BQ123. Animals in insulin/saline group showed a signiﬁcant increase
(160%) in cerebral blood perfusion compared to baseline. This increase
in cerebral perfusion was attenuated by BQ123 or BMS-182874.
Treatment with BQ123 also improved blood pH and ketones in DKA
rats. It can be concluded that ETA receptor antagonists maybe of
therapeutic use in the management of DKA and its complications.
doi:10.1016/j.lfs.2014.01.046
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